NasdaqCM - Delayed Quote • USD
Bio-Path Holdings, Inc. (BPTH)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -4.54 | -4.6 | -18.71 | -18.41 |
| Low Estimate | -4.54 | -4.6 | -18.71 | -18.41 |
| High Estimate | -4.54 | -4.6 | -18.71 | -18.41 |
| Year Ago EPS | -13.2 | -10.6 | -33.63 | -18.71 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -9 | -10.4 | -6.8 | -5.4 |
| EPS Actual | -13.2 | -10.6 | -6.4 | -7.05 |
| Difference | -4.2 | -0.2 | 0.4 | -1.65 |
| Surprise % | -46.70% | -1.90% | 5.90% | -30.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -4.54 | -4.6 | -18.71 | -18.41 |
| 7 Days Ago | -4.54 | -4.6 | -18.71 | -18.41 |
| 30 Days Ago | -4.8 | -5 | -20.8 | -20.4 |
| 60 Days Ago | -0.24 | -0.25 | -1.04 | -1.02 |
| 90 Days Ago | -0.24 | -0.25 | -1.04 | -1.02 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BPTH | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 65.60% | -- | -- | 1.60% |
| Next Qtr. | 56.60% | -- | -- | 10.50% |
| Current Year | 44.40% | -- | -- | 5.20% |
| Next Year | 1.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Roth MKM: Buy to Buy | 4/18/2024 |
| Maintains | Roth MKM: Buy to Buy | 3/27/2024 |
Related Tickers
ATNF 180 Life Sciences Corp.
1.8201
-0.54%
AKTX Akari Therapeutics, Plc
1.1662
-0.32%
RNAZ TransCode Therapeutics, Inc.
0.4850
-3.39%
BRTX BioRestorative Therapies, Inc.
1.3700
-2.84%
TENX Tenax Therapeutics, Inc.
3.6300
-1.63%
PCSA Processa Pharmaceuticals, Inc.
1.5800
+1.28%
PHIO Phio Pharmaceuticals Corp.
0.6399
+0.77%
FNCH Finch Therapeutics Group, Inc.
2.2400
-4.68%
NBY NovaBay Pharmaceuticals, Inc.
0.0824
-1.90%
VCNX Vaccinex, Inc.
4.8600
+3.40%